Moderna today announced the administration of first COVID-19 vaccine doses to participants between the ages of 6 months and 12 years old as part of a phase 2/3 clinical trial. 

The trial will investigate the vaccine’s effectiveness and safety in 6,750 healthy pediatric participants. For this study, Moderna will investigate two dosing levels for those ages 2 to 12, and three dosing levels for those aged 6 months to 2 years old.

Related News Articles

Headline
The Food and Drug Administration does not currently authorize the monoclonal antibody bamlanivimab for emergency use to treat mild-to-moderate COVID-19 in the…
Headline
In a study of symptomatic adults tested for SARS-CoV-2 at U.S. pharmacies since Sept. 14, bivalent COVID-19 vaccine boosters provided additional protection…
Headline
The Biden Administration today launched a six-week campaign to encourage Americans to get an updated COVID-19 vaccine. In addition to ongoing pop-up clinics,…
Headline
Children under age 5 are more likely to receive a COVID-19 vaccine if their parents perceive it as safe and their health care provider recommends it, according…
Headline
AHA this week released a new Thanksgiving-focused toolkit to help promote pediatric COVID-19 vaccination on social media, including sample content and graphics…
Headline
The Food and Drug Administration recently updated its health care provider fact sheet on bebtelovimab to note that the monoclonal antibody is not expected…